[Form 4] Vaxcyte, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Elvia Cowan, SVP Finance at Vaxcyte, Inc. (PCVX), reported the disposition of 482 shares of the issuer's common stock on 09/08/2025 at a reported price of $32.41 per share. The filing shows 26,156 shares were beneficially owned by the reporting person after the transaction and identifies the ownership form as direct.

The form explains these 482 shares were surrendered to the company to satisfy tax-withholding obligations arising when restricted stock units vested. The Form 4 was signed on behalf of Elvia Cowan by an attorney-in-fact on 09/10/2025.

Insights

Corporate Governance Expert

TL;DR: Routine tax-withholding share surrender by an officer; not an active market sale signal.

The disclosure documents a common insider action where vested RSUs are withheld by the issuer to cover taxes. This reduces the officer's reported share count by a small amount (482 shares) and leaves a substantial remaining holding (26,156 shares). There is no indication of an open-market sale or change in control, and the filing adheres to standard Section 16 reporting requirements.

Securities Analyst

TL;DR: Transaction reflects tax-related surrender of shares; immaterial to company valuation in isolation.

The transaction price listed is $32.41 and the action is coded as a disposition resulting from tax withholding upon RSU vesting. Such transactions typically have no cash proceeds to the insider and do not signal strategic shifts. The remaining direct ownership of 26,156 shares should be viewed in context of overall insider holdings and company float for materiality assessment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cowan Elvia

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		F		482(1)	D	$32.41	26,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.

Remarks:

	Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Elvia Cowan report on Form 4 for Vaxcyte (PCVX)?

The filing reports the disposition of 482 shares on 09/08/2025 at a price of $32.41 per share.

Why were the 482 shares surrendered according to the Form 4?

The filing states the shares were surrendered to cover tax withholding obligations realized when restricted stock units vested.

How many shares did the reporting person own after the transaction?

The Form 4 reports 26,156 shares beneficially owned by the reporting person following the transaction.

What is the reporting person's role at Vaxcyte and how was the form signed?

Elvia Cowan is listed as SVP, Finance. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/10/2025.

Does the Form 4 indicate an open-market sale?

No. The Form 4 explains the disposition was due to tax withholding on vested RSUs, not an open-market sale.